Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.



Unveiling the Latest in HER2+ Breast Cancer and Beyond With Drs Sara Hurvitz and Neil Iyengar

Tamoxifen reduced the risk of invasive ipsilateral breast recurrence in patients with good-risk ductal carcinoma in situ.

Tamoxifen Reduces Ipsilateral Breast Recurrence in Good-Risk Ductal CIS

Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.

Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer

Patients with luminal B and HER2E breast cancer subtypes may have a greater PFS benefit with ribociclib plus endocrine therapy vs combination chemotherapy.

Certain Breast Cancer Subtypes May Derive a Greater Benefit With Ribociclib Combo vs Chemo

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

Articles

Dana-Farber Cancer Institute investigators found that women reported having similar QOL whether they received active monitoring or surgery for low-risk ductal carcinoma in-situ.



Study Finds Quality of Life Maintained With Active Monitoring for DCIS

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

Pacritinib and momelotinib both demonstrated favorable real-world effects on anemia and transfusion requirements among patients with myelofibrosis.

Pacritinib and Momelotinib Display Positive Real-World Impact on Anemia and Transfusion Needs in Myelofibrosis

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Third-Line Treatment Options for Metastatic Colorectal Cancer 

Unmet Needs in Third-Line mCRC: Challenges and Opportunities 

What are the most significant unmet needs currently in treating mCRC in the third-line setting?

What additional research is needed to improve patient outcomes? Are there any investigational agents that you are excited about? (potential list below, feel free to comment on any others)

Videos

Panelists discuss how current third-line treatment options for metastatic colorectal cancer, including regorafenib, trifluridine-tipiracil plus bevacizumab, and fruquintinib, are selected based on patient-specific factors, safety profiles, and treatment goals, while also exploring future directions and unmet needs in mCRC management.

Panelists discuss their preferred treatment options for patients in the third-line setting of metastatic colorectal cancer (mCRC), focusing on regorafenib, trifluridine-tipiracil plus bevacizumab, and fruquintinib, and share insights on how patient and disease-specific factors influence the selection of the most appropriate regimen for each clinical scenario.

Navigating mCRC: Treatment Options in the Third-Line Setting

Panelists discuss how “refractory” metastatic colorectal cancer (mCRC) is defined in the third- vs fourth-line setting, and the treatment goals in the third-line setting, focusing on optimizing patient outcomes and managing progression after prior therapies.

Nuances With Defining “Refractory” mCRC in the Third-Line Setting

Panelists discuss how patient preferences and lifestyle factors are considered when selecting between treatment options for third-line metastatic colorectal cancer (mCRC) and speak about their approaches to shared decision-making and optimal sequencing of therapies based on clinical context and patient needs.

Treatment Sequencing in mCRC: Balancing Expert Perspectives and Shared Decision-Making With Patients

Panelists discuss their perspectives on the SUNLIGHT trial and how its active-arm comparator design, compared with placebo-controlled trials like FRESCO-2 and CORRECT, influences their treatment approach, while also exploring how specific efficacy outcomes impact their decision-making in third-line metastatic colorectal cancer.

Perspectives on the SUNLIGHT Trial: Study Design and Outcomes

Panelists discuss how health-related quality of life (HRQOL) data influence their treatment decisions for third-line metastatic colorectal cancer (mCRC), how they assess patient symptoms and quality of life in clinical practice, and how the toxicity profiles of different therapies guide their treatment choices.

Factoring in Health-Related Quality of Life Outcomes in mCRC Treatment Selection

Panelists discuss the common toxicities associated with trifluridine-tipiracil plus bevacizumab in clinical practice, including their typical severity, and share their strategies for managing dose reductions and interruptions due to cytopenias when treating patients with this regimen.

Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab

Panelists discuss the frequency of hypertension observed with trifluridine-tipiracil plus bevacizumab and their strategies for monitoring and managing it, as well as their approach to dosing TAS-102 plus bevacizumab in patients with hepatic or renal impairment. They also review common toxicities associated with fruquintinib and regorafenib, including hypertension, hand-foot syndrome, and hepatotoxicity, and share management strategies for these adverse events.

Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment

Panelists discuss the most significant unmet needs in treating third-line metastatic colorectal cancer (mCRC), highlight areas where additional research is needed to improve patient outcomes, and explore investigational agents they find promising for future treatment options.

Unmet Needs in Third-Line mCRC: Challenges and Opportunities

Unmet Needs in Third-Line mCRC: Challenges and Opportunities

EP: 1.Navigating mCRC: Treatment Options in the Third-Line Setting

EP: 2.Nuances With Defining “Refractory” mCRC in the Third-Line Setting

EP: 3.Treatment Sequencing in mCRC: Balancing Expert Perspectives and Shared Decision-Making With Patients

EP: 4.Perspectives on the SUNLIGHT Trial: Study Design and Outcomes

EP: 5.Factoring in Health-Related Quality of Life Outcomes in mCRC Treatment Selection

EP: 6.Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab

EP: 7.Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment

EP: 8.Unmet Needs in Third-Line mCRC: Challenges and Opportunities

Latest Conference Coverage